Nuformix PLC Statement re. Share Price Movement (1806R)
25 Octubre 2019 - 5:11AM
UK Regulatory
TIDMNFX
RNS Number : 1806R
Nuformix PLC
25 October 2019
25th October 2019
Nuformix plc
("Nuformix" or "the Company"),
Statement re. Share Price Movement
Nuformix, the pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs notes the recent share price movement and press
reports. It confirms that the Company is in discussion with
multiple potential licensees in Japan and Asia, including but not
limited to its NXP002 programme.
Discussions are on-going. However, no final agreement has been
reached and no guarantees can be provided that the on-going
discussions will result in material agreements for the Company.
Further update announcements will be made as and when
appropriate.
Market Abuse Regulation (MAR) Disclosure. Certain information
contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 until the publication of this announcement via a
Regulatory Information Service and accordingly, this inside
information is now considered to be in the public domain.
Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive
Officer +44 (0)1223 62722
Email: info@nuformix.com
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix's risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix's IP portfolio of granted patents covers cocrystal
forms of five small molecule drugs. Nuformix is targeting
high-value unmet needs with its lead programmes in oncology
supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested
in pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX.L.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
SPMGMMZGGKNGLZM
(END) Dow Jones Newswires
October 25, 2019 06:11 ET (10:11 GMT)
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024